Please login to the form below

Cellectis

This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare. Cellectis gains senior scientist from Novartis. ... on the development and long-term strategic planning for Cellectis’ innovative product portfolio,” said Dr.

Latest news

Sangamo bulks up in cell therapy with TxCell acquisition

Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.
Gilead signs $3bn-plus gene-editing deal with Sangamo

The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured
Cellectis floored by patient death in CAR-T trial

It may be that the FDA will exercise greater caution in Cellectis' case. ... UCART19 is partnered with Servier and Pfizer. Cellectis' Nasdaq-listed shares are currently trading at around $25, down from more than $32 ahead of the patient death announcement
Servier cleared to start US trials CAR-T therapy

The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’ CAR-T
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

Cellectis has been given the go-ahead by the FDA to start trials of its CAR-T immunotherapy UCART123 in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients however.

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Deal Watch November 2015

379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
Pharma deals in May 2015

Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.
Pharma deals in March 2015

Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck
Deal Watch table for June 2014

350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.
Pharma deals during June 2014

Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.
Cellectis’ Mathieu Simon will serve as interim chief medical officer

He will take over the responsibilities of Loan Hoang-Sayag. Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag, who has ... As current executive vice president and chief operating officer,
Rainer Boehm and Hervé Hoppenot join Cellectics board

I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. ... I am excited to be joining the Cellectis board during this important time of growth.”.
Dr Niall Murphy and Pierre Schwich join Pharnext

Meanwhile, Pierre Schwich (pictured left) joins Pharnext from Cellectis where he served as chief financial officer from 2011 until 2014. ... Before joining Cellectis, he served as chief financial officer and corporate secretary for Genesys Conferencing,

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Director – Health Policy – Global Agency: Salary TBC

Account Director, Medical Education: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Associate Director: £75, 000-90, 000

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager / Account Director: Competative

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Medical Writer: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Medical Writer: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...